PAI
CRSP icon

Pittenger & Anderson Inc’s CRISPR Therapeutics CRSP Stock Holding History

Pittenger & Anderson Inc’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$63K Hold
1,325
– – ﹤0.01% 298
2025
Q4 		$69.5K Buy
+1,325
New +$79.4K ﹤0.01% 289
2021
Q4 		– Sell
-36
Closed -$4K – 459
2021
Q3 		$4K Buy
36
+11
+44% +$1.38K ﹤0.01% 399
2021
Q2 		$4K Buy
25
+8
+47% +$973 ﹤0.01% 365
2021
Q1 		$2K Hold
17
– – ﹤0.01% 373
2020
Q4 		$3K Buy
17
+6
+55% +$709 ﹤0.01% 344
2020
Q3 		$1K Buy
+11
New +$976 ﹤0.01% 355

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Pittenger & Anderson Inc's CRSP Position: Q1 2026 in Review

Pittenger & Anderson Inc held its CRISPR Therapeutics (CRSP) position steady in Q1 2026 at 1,325 shares worth $63K. The position accounts for ﹤0.01% of the portfolio, ranked #298.

Pittenger & Anderson Inc first reported a position in CRSP in Q3 2020 and has held it in 7 quarters since. The position peaked at $69.5K in Q4 2025. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Pittenger & Anderson Inc held 1,325 shares of CRISPR Therapeutics worth $63K as of Q1 2026.
  • Pittenger & Anderson Inc left its CRISPR Therapeutics share count unchanged in Q1 2026.
  • CRISPR Therapeutics made up ﹤0.01% of Pittenger & Anderson Inc's portfolio in Q1 2026, its #298 holding.
  • Pittenger & Anderson Inc first reported a position in CRISPR Therapeutics in Q3 2020 and has held it in 7 quarters since.
  • Pittenger & Anderson Inc's CRISPR Therapeutics position peaked at $69.5K in Q4 2025.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Pittenger & Anderson Inc's 13F filing for Q1 2026, filed 1 May 2026.